|
|
European Biopharmaceutical Enterprises Appoints Søren Tulstrup, President & CEO of Santaris Pharma A/S, to its Board of Directors |
| |
|
|
Santaris Pharma A/S and miRagen Therapeutics, Inc. Form Strategic Alliance to Develop microRNA-targeted Medicines for the Treatment of Cardiovascular Disease |
| |
|
|
Santaris Pharma A/S Receives Red Herring Top 100 Europe Award |
| |
|
|
Santaris Pharma A/S advances RNA-targeted drug development candidate against PCSK9, an important new target for the treatment of high cholesterol |
| |
|
|
New data show breakthrough microRNA-targeted therapy developed using Santaris Pharma A/S proprietary LNA technology holds promise as new treatment for Hepatitis C |
| |
|
|
Santaris Pharma A/S expands executive team, appoints Chief Medical Officer and Chief Business Officer to advance proprietary RNA-targeted drug development programs |
| |
|
|
Santaris Pharma's Interim Report 1 January - 30 September 2009 published |
| |
|
|
New collaborations and breakthrough advancements in RNA-based drug development programs lead Santaris Pharma A/S to establish US operations |
| |
|
|
Santaris Pharma A/S forms strategic alliance with Shire plc to develop RNA-based medicines for the treatment of rare genetic disorders |
| |
|
|
Original paper: microRNAs in CNS disorders published in Neuromol Med |
| |
|
|
Santaris Pharma presents at the World Summit of Antivirals |
| |
|
|
Advance Access publication in Nucleic Acid Research on silencing of miRNA-155 in mice |
| |
|
|
LNA-based HIF-1 alpha inhibitor shows early signs of clinical benefit |
| |
|
|
Santaris Pharma Director appointed Adjunct Professor in RNA Biology |
| |
|
|
Santaris Pharma director udnævnt til adjungeret professor i RNA biologi på Aalborg Universitet |
| |
|
|
Santaris Pharma presents at Tides, Las Vegas |
| |
|
|
Santaris Pharma invited speaker at microSymposium 2009, Vienna |
| |
|
|
Santaris Pharma delivers six LNA-based RNA inhibitors to Enzon Pharmaceuticals ahead of schedule |
| |
|
|
Santaris Pharma presents at Keystone Meeting in April |
| |
|
|
LNA-based RNA oligonucleotides potently inhibit cancer-associated microRNAs |
| |
|
|
Another LNA-based RNA Inhibitor Enters Clinical Trials |
| |
|
|
LNA used to silence microRNA in murine brain |
| |
|
|
Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines |
| |
|
|
Santaris Pharma Releases Positive Data on LNA-based Survivin Inhibitor |
| |
|
|
New class of drug candidates developed by Santaris Pharma can potently counteract disease-associated microRNAs |
| |
|
|
Santaris Pharmas microRNA lægemiddelkandidater hæmmer effektivt sygdomsrelaterede microRNA’er |
| |
|
|
FierceBiotech Names Santaris Pharma as One of the “Fierce 15" Biotech Companies of 2008 |
| |
|
|
Santaris Pharma kåret som “Fierce 15" virksomhed af FierceBiotech |
| |
|
|
Søren Tulstrup Appointed President & CEO of Santaris Pharma A/S |
| |
|
|
Søren Tulstrup ny President & CEO i Santaris Pharma |
| |
|
|
Santaris Pharma afprøver verdens første microRNA |
| |
|
|
Santaris Pharma begins human clinical testing of world's first microRNA |
| |
|
|
Santaris Pharma Consortium awarded 45m DKK |
| |
|
|
Højteknologifonden donerer 45 millioner kroner til Santaris Pharma Konsortium som støtte til udviklingen af RNA lægemidler |
| |
|
|
Nature publishes study by Santaris Pharma scientists and collaborators: LNA-mediated microRNA silencing in non-human primates |
| |
|
|
Santaris Pharma to present at the Rodman & Renshaw 10th Annual healthcare Conference |
| |
|
|
Santaris Pharma præsenterer på BioIndustry Organisations 10. årlige CEO & Investor Konference |
| |
|
|
GlaxoSmithKline og Santaris Pharma indgår global forsknings- og udviklingsalliance. Formålet er at identificere, udvikle og markedsføre RNA antagonister som nye lægemidler mod virussygdomme |
| |
|
|
GlaxoSmithKline and Santaris Pharma enter global R&D alliance to discover, develop and commercialise RNA antagonists as novel antivirals |
| |
|
|
20 millioner Euro til Santaris Pharma |
| |
|
|
Santaris Pharma raises €20 million of new equity |
| |
|
|
Santaris Pharma’s HIF-1 alpha antagonist begins second phase 1 study |
| |
|
|
Højteknologifonden støtter udvikling af nyt banebrydende microRNA lægemiddel |
| |
|
|
Santaris Pharma consortium awarded €1.35m by Denmark’s Advanced Technology Foundation for development of the first microRNA medicine |
| |
|
|
Hanne Damgaard Jensen appointed as SVP Product Development |
| |
|
|
Dr Flemming Ørnskov appointed Chairman of Santaris Pharma Board |
| |
|
|
Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research |
| |
|
|
FDA godkender Enzons ansøgning om klinisk afprøvning af Santaris Pharmas andet nye lægemiddel mod cancer |
| |
|
|
FDA approves Enzon IND for Santaris Pharma’s Second New Cancer Drug |
| |
|
|
Dr Walter Wenninger appointed to Santaris Pharma Board |
| |
|
|
Walter Wenninger udnævnt til bestyrelsesmedlem i Santaris Pharma |
| |
|
|
Santaris Pharma awarded Ernst & Young Entrepreneur of the Year 2006 |
| |
|
|
Santaris Pharma to present at Rodman & Renshaw 8th Annual Healthcare Conference - November 6th 2006 |
| |
|
|
Claus Bræstrup, CEO Lundbeck, udnævnt til Santaris Pharmas bestyrelse |
| |
|
|
Claus Braestrup, CEO of Lundbeck, appointed to Santaris Pharma Board |
| |
|
|
Enzon and Santaris Pharma enter into Global Collaboration to Develop Novel Cancer Therapeutics |
| |
|
|
Santaris Pharma to present at Rodman & Renshaw 3rd Annual Global Health Care Conference |
| |
|
|
New MicroRNA Cancer Research Collaboration |
| |
|
|
Nyt MicroRNA-Forskningskonsortium |
| |
|
|
Santaris Pharma raises EUR 40m of new equity |
| |
|
|
Santaris Pharma rejser EUR 40 millioner i ny kapital |
| |
|
|
FDA approves IND for SPC2996 |
| |
|
|
Santaris Pharma to present at Rodman & Renshaw 7th Annual Healthcare Conference – November 8th 2005 |
| |
|
|
Santaris Pharma sikrer mellemfinansiering på EUR 4,4 millioner (DKK 32,4 millioner) fra Selskabets hovedaktionærer og indleder Selskabets anden finansieringsrunde |
| |
|
|
Santaris Pharma raises EUR 4.4 million |
| |
|
|
Santaris Pharma initiates Phase I/II multi-centre clinical trial in Chronic Lymphocytic Leukaemia |
| |
|
|
Santaris Pharma to present at Rodman & Renshaw Global Healthcare Conference - May 4th 2005 |
| |
|
|
LNA inhibits siRNA-mediated induction of interferon. |
| |
|
|
LNA in siRNA Therapy: New Findings |
| |
|
|
Lene Worsaae Dalby appointed VP Clinical Development |
| |
|
|
Santaris Pharma raises EUR 4.4 million in interim funding from lead investors and launches second round financing |
| |
|
|
Santaris Pharma appoints new CFO |
| |
|
|
Santaris Pharma A/S wins decision in patent opposition case |
| |
|
|
Nordic Biotechnology Merger |
| |